<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525848</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008718/ reference no. 104</org_study_id>
    <nct_id>NCT02525848</nct_id>
  </id_info>
  <brief_title>Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries</brief_title>
  <acronym>PONV</acronym>
  <official_title>Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of pre-empetive administration of Aprepitant, Versus Gabapentin
      prophylaxis for reducing the incidence of postoperative nausea and vomiting in Laproscopic
      gynacological surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative nausea and vomiting (PONV) is frequently encountered in the surgical recovery
      room. Laparoscopic surgery is one important risk factor for increased incidence of PONV.
      Gabapentin, an anticonvulsant with known postoperative analgesic properties, has shown some
      activity against PONV. Results from clinical trials evaluating the anti-emetic efficacy of
      gabapentin are conflicting.

      Aprepitant, a neurokinin-1 (NK1) receptor antagonist, blockades the central effects of
      substance P. Substance P is a neurotransmitter found in central areas associated with emesis
      such as the dorsal vagal complex and area postrema.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence (%) of postoperative nausea and vomiting</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>The incidence (%) of PONV will be recorded each 6 hours until 24 hours after discharge from the PACU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>non invasive blood pressure</measure>
    <time_frame>intra-operative from induction of general anesthesia till end of surgery.</time_frame>
    <description>Noninvasive blood pressure measured immediately after induction of anesthesia ,15 min.30 min.45 min. and 60 min till the end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>Intra-operative from induction of anesthesia till end of surgery.</time_frame>
    <description>heart rate recorded immediately after induction of anesthesia ,15 min.30 min.45 min. and 60 min till the end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>24 h postoperative.</time_frame>
    <description>Side effects of given drugs will be treated and recorded</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous dexamethasone 8 mg 2 minutes before induction of anesthesia;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gapabentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral gabapentin 600 mg 1 hour before induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aprepitan 80mg 1 hour before induction of anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>dexamethasone 8 mg iv 2 minutes before induction of anesthesia</description>
    <arm_group_label>dexamethasone</arm_group_label>
    <arm_group_label>gapabentin</arm_group_label>
    <arm_group_label>Aprepitant</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>oral gabapentin 600 mg 1 hour before induction of anesthesia</description>
    <arm_group_label>gapabentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>oral aprepitan 80mg 1 hour before induction of anesthesia.</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ ASA physical status I and II aged between 18 and 45 yrs. They undergo Laproscopic
        gynacological surgeries under general anesthesia.

        Exclusion Criteria:

          -  Central or peripheral neurological pathologies.

          -  History of drug abuse, chronic pain, or psychiatric disorders.

          -  Pregnant women

          -  Patients who took sedatives, antiemetics, or antipruritics within 24 hrs of operation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala S Abdel-Ghaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisstant professor in Anesthesia and intensive care department, faculty of medicine, Assiut university, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hala saad Abdel-Ghaffar</name>
      <address>
        <city>Assiut</city>
        <state>Assiut governorate</state>
        <zip>715715</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hala Saad Abdel-Ghaffar</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

